The therapeutic use of messenger RNA (mRNA) has fueled great hope to combat a wide
range of incurable diseases. Recent rapid advances in biotechnology and molecular …

Over the past several decades, messenger RNA (mRNA) vaccines have progressed from a
scepticism-inducing idea to clinical reality. In 2020, the COVID-19 pandemic catalysed the …

Lipid nanoparticles (LNPs) have emerged across the pharmaceutical industry as promising
vehicles to deliver a variety of therapeutics. Currently in the spotlight as vital components of …

The recent success of mRNA vaccines in SARS-CoV-2 clinical trials is in part due to the
development of lipid nanoparticle delivery systems that not only efficiently express the …

Vaccination represents the best line of defense against infectious diseases and is crucial in
curtailing pandemic spread of emerging pathogens to which a population has limited …

Over the past decade, messenger RNA (mRNA) has emerged as potent and flexible platform
for the development of novel effective cancer immunotherapies. Advances in non-viral gene …

Lipid nanoparticle (LNP)-formulated mRNA vaccines were rapidly developed and deployed
in response to the SARS-CoV-2 pandemic. Due to the labile nature of mRNA, identifying …

Therapeutic RNA molecules possess high potential for treating medical conditions if they
can successfully reach the target cell upon administration. However, unmodified RNA …

There has been increased interest in the development of RNA-based vaccines for protection
against various infectious diseases and also for cancer immunotherapies. Rapid and cost …

Lipid nanoparticles (LNPs) have been one of the most successful nano-delivery vehicles
that enable efficient delivery of cytotoxic chemotherapy agents, antibiotics, and nucleic acid …